20.500.12556/DiRROS-19620 Simvastatin is effective in killing the radioresistant breast carcinoma cells Background. Statins, small molecular 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are widely used to lower cholesterol levels in lipid-metabolism disorders. Recent preclinical and clinical studies have shown that statins exert beneficial effects in the management of breast cancer by increasing recurrence free survival. Unfortunately, the underlying mechanisms remain elusive. Materials and methods. Simvastatin, one of the most widely prescribed lipophilic statins was utilized to investigate potential radiosensitizing effects and an impact on cell survival and migration in radioresistant breast cancer cell lines. Results. Compared to parental cell counterparts, radioresistant MDA-MB-231-RR, T47D-RR andAu565-RR cells were characterized by upregulation of 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMGCR) expression accom-panied by epithelial-to-mesenchymal transition (EMT) activation. Radioresistant breast cancer cells can be killed by simvastatin via mobilizing of a variety of pathways involved in apoptosis and autophagy. In the presence of simvasta-tin migratory abilities and vimentin expression is diminished while E-cadherin expression is increased. Conclusions. The present study suggests that simvastatin may effectively eradicate radioresistant breast carcinoma cells and diminish their mesenchymal phenotypes. radiotherapy breast cancer radioresistant cells radioterapija rak dojke radiorezistentne celice true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-07-22 14:53:03 2024-07-22 14:53:04 2024-07-23 03:55:56 0000-00-00 00:00:00 2021 0 0 str. 305-316, VI no. 3 Vol. 55 Sep. 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2021-09-01 602 1318-2099 10.2478/raon-2021-0020 78947843 https://sciendo.com/article/10.2478/raon-2021-0020 1 933ad43a-4818-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=27122 RAZ_Aschenbrenner_Bertram_2021.pdf RAZ_Aschenbrenner_Bertram_2021.pdf 1 6EA4208607993EC488B9FD489B0C765C 12cb008af104b6b78a99d37e56b9205517f9a81ee7eb064a0d6ac8498a741175 bfc1c941-4818-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=27123 Onkološki inštitut Ljubljana 0 0 0